DRUG SUBSTANCE DEVELOPMENT

Drug substance development

Comprised of more than 150 scientists in four countries, we exceed expectations on even the most challenging projects. Working in state-of-the-art laboratories equipped with the latest process and analytical instrumentation, we efficiently conduct route scouting, rapid process development and optimization of reaction conditions for scale-up of materials for preclinical trials or large-scale manufacturing, including non-GMP and GMP. With support from our expert team of analysts, chemical engineers and QA professionals, we rapidly and efficiently develop scalable manufacturing processes to meet any need, including the development of high-potency APIs and DEA-licensed controlled substances.



Milligram to Gram
Discovery

Gram to 100 kg +
Development

100 kg + to metric tons
Manufacturing

Development platform

Leverage Curia's small molecule API early development platform and GMP suites at our U.S., India, Spain and Germany-based facilities for worldwide access to premium CDMO services.



Additional services include solid state characterization (e.g., polymorph screening and crystallization), route scouting, stability studies and supporting analytical activities, like impurity screening and additional method development.

Comprehensive Drug Substance Development Capabilities

Phase	Albany, NY	Rensselaer, NY	Springfield, MO	Frankfurt, DE	León, ES	San Cristóbal, ES	Valladolid, ES	Bon-Encontre, FR	Origgio, IT	Rozzano, IT	Hyderabad, IN
Preclinical	●			●	●	●	●	●			●
Phase I	●	●	●	●	●	●	●	●	●	●	●
Phase II	●	●	●	●	●	●	●	●	●	●	●
Phase III	●	●	●				●	●	●	●	
Commercial		●	●				●	●	●	●	

Core technologies

High potency

Our high-potency network is SafeBridge® certified. This designation takes into account not only facility infrastructure, but also management and all protocols when it comes to highly potent handling. Curia also has a strong compliance record, helping launch multiple new highly potent APIs into the marketplace. Curia also has a long history of handling highly potent compounds with over 50 highly potent projects across our Curia service offerings.

Lipids

Curia is a pioneer in developing and manufacturing lipids, and we were key players in supporting COVID-19 vaccine developers with their lipid supply chains. Our teams operate seamlessly across multiple sites, planning activities in parallel to compress timelines when appropriate for your project. We also select the appropriate site based on the unique process, analytical and chromatographic needs of your project.

Fermentation

Curia's dedicated fermentation development team combines state-of-the-art facilities with expert knowledge to deliver customized solutions, from development to manufacturing. Our track record showcases unparalleled quality and regulatory compliance. With a multidisciplinary approach and versatile feedback control systems, we are adept at tackling challenges from benchtop experiments to full-scale production.

API Sterilization

Our scientists apply high-performance microfiltration to accomplish sterilization. We often use this technology with powder, which is dissolved, filtered and crystallized. Microfiltration is nondestructive, which means it differs fundamentally from traditional sterilization methods. We offer many techniques to precisely control the physical properties of the final product as well as aseptic packaging customization